Business Context and Reporting Period
Company: Relmada Therapeutics, Inc. (RLMD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Relmada is a clinical-stage biotechnology company that substantially redesigned its development pipeline in 2025. Following the termination of its esmethadone (REL-1017) and psilocybin (REL-P11) programs due to futility or strategic shifts, the Company pivoted to two new lead candidates: NDV-01 (a novel intravesical formulation for non-muscle invasive bladder cancer) and sepranolone (a neurosteroid for Prader-Willi syndrome and Tourette Syndrome). The Company has no commercial products and has not generated revenue.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Loss | $(57,385,200) | $(79,979,400) |
| Net Loss Per Share (Basic/Diluted) | $(1.45) | $(2.65) |
| Research & Development Expense | $26,879,100 | $46,175,500 |
| General & Administrative Expense | $32,221,100 | $37,715,500 |
| Cash Used in Operating Activities | $(45,786,988) | $(51,755,798) |
| Cash Provided by Financing Activities | $93,564,808 | $(40,341) |
| Cash and Cash Equivalents (Year End) | $3,496,540 | $3,857,026 |
| Short-Term Investments (Year End) | $89,509,710 | $41,052,356 |
| Total Liquidity (Cash + Investments) | $93,006,250 | $44,909,382 |
| Accumulated Deficit | $(698,267,200) | $(640,882,035) |
Material Changes vs. Prior Period
- Strategic Pivot: Terminated the esmethadone (REL-1017) program in July 2025 and the psilocybin (REL-P11) program in May 2025. Acquired sepranolone (Feb 2025) and in-licensed NDV-01 (March 2025).
- Expense Reduction: Total operating expenses decreased by approximately $24.8 million year-over-year. R&D expenses dropped $19.3 million, primarily due to reduced consultant fees for terminated Phase 3 trials and lower stock-based compensation. G&A expenses decreased $5.5 million, driven by a $10.7 million reduction in stock-based compensation.
- Financing Activity: In November 2025, the Company raised approximately $94 million through an underwritten offering of common stock and pre-funded warrants. This significantly improved liquidity compared to 2024.
- Investment Portfolio: Short-term investments increased by approximately $48.5 million, reflecting the deployment of capital raised in late 2025.
Guidance, Outlook, and Risks
Outlook and Milestones
- NDV-01: Phase 2 data showed a 76% complete response rate at 12 months in high-risk NMIBC. The Company expects to initiate Phase 3 trials for two indications (high-risk BCG-unresponsive and intermediate-risk adjuvant) in mid-2026.
- Sepranolone: Phase 2a data in Tourette Syndrome showed a 28% reduction in tic severity. A Phase 2 pilot study in Prader-Willi Syndrome is expected to initiate in mid-2026.
- Liquidity: Management believes existing cash and investments ($93 million as of Dec 31, 2025) plus a subsequent $160 million PIPE financing closed in March 2026 will fund operations for at least 12 months from the filing date.
Risks and Contingencies
- Going Concern: While the 2024 audit included a going concern qualification, the 2025 financing alleviated substantial doubt regarding the Company's ability to continue as a going concern.
- Regulatory Risk: Success depends entirely on FDA approval of NDV-01 and sepranolone. Clinical trial results may not be predictive of future outcomes.
- Stock Price Volatility: The Company faced Nasdaq delisting warnings in early 2025 due to low bid price but regained compliance in September 2025.
- Intellectual Property: Reliance on third-party licenses (Trigone, Asarina) and potential patent challenges.
Investor Verification Checklist
- Capital Runway: Verify the closing and net proceeds of the $160 million PIPE financing announced in March 2026 to confirm the 12-month liquidity runway.
- Clinical Data: Review the full 12-month Phase 2 data for NDV-01 and the Phase 2a data for sepranolone to assess the robustness of the efficacy signals.
- License Obligations: Confirm the milestone payment structure for NDV-01 (up to $200 million) and the royalty terms (3% of net sales) with Trigone Pharma.
- Stock-Based Compensation: Monitor future equity grants, as the 2021 Equity Incentive Plan had limited shares available for issuance in 2025, potentially impacting future compensation expenses.
- Nasdaq Compliance: Monitor the stock price to ensure continued compliance with the $1.00 minimum bid price requirement.